# Sichuan Baili Pharmaceutical Co., Ltd.: Phase 2 study closed enrollment, 76 enrolled (Non-small Cell Lung Cancer)

**Score:** 65/100

| Field | Value |
|---|---|
| Sponsor | Sichuan Baili Pharmaceutical Co., Ltd. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer |
| NCT ID | NCT06498986 |
| Phase | Phase 2 |
| Status | active not recruiting |
| Conditions | Non-small Cell Lung Cancer |
| Intervention types | drug |
| Target enrollment | 76 |
| Site countries | China |
| Posted | 2024-07-12 |
| Planned start | 2024-07-31 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-09 |
| Last update posted | 2026-10-09 |

## Why this score
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 2: multi-site, larger budget.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT06498986). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.